• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients

September 25, 2017 By Sarah Faulkner

Radiation, chemo combo improves survival for advanced-stage NSCLC patients

ASTROAccording to data from a Phase II trial presented at ASTRO today, combining radiation therapy and chemotherapy could help curb disease progression for patients with limited metastatic non-small cell lung cancer.

Progression-free survival went from 3.5 months to 9.7 months when patients were treated with the addition of radiation therapy at all the metastatic sites of lung cancer, as well as the primary disease site. Side effects related to treatment were similar between the groups receiving the combination therapy and those treated with just chemotherapy, the researchers reported.

“Even in the era of immunotherapy, there are not large numbers of metastatic NSCLC patients with durable responses to systemic therapy. In our trial, however, the addition of radiation therapy directed at each of the cancerous areas greatly improved how patients responded to subsequent rounds of chemotherapy,” lead author Dr. Puneeth Iyengar said in prepared remarks. “This finding suggests that local treatments, including radiation, could work in concert with chemotherapy to prolong the amount of time before recurrence occurs in patients with limited sites of metastatic NSCLC.”

The Phase II trial, which enrolled 29 patients, evaluated whether the addition of local consolidative radiation therapy to the standard treatment of systemic therapy boosts progression-free survival for patients with limited metastatic NSCLC.

Patients were randomized to receive maintenance chemotherapy alone or a combination of stereotactic ablative radiotherapy to all sites of the disease followed by maintenance chemotherapy.

An interim analysis showed a median progression-free survival rate of 9.7 months with consolidative radiation therapy followed by chemotherapy, compared to 3.5 months for maintenance chemotherapy alone.

“These findings verify that progression-free survival for limited metastatic disease really is no different than it is for widely metastatic disease, suggesting that local therapy could play an important future role in survival outcomes,” Iyengar added. “Moreover, the addition of consolidative radiation did not increase toxicity, which allowed patients to continue on to additional systemic therapy that is important to controlling aggressive metastatic disease.
“There is a significant possibility that local therapy, such as consolidative radiation, may become an important part of the management of limited metastatic NSCLC patients, but this validation must take place in randomized phase III studies. Interested patients should seek more information about the ongoing NRG LU 002 and Saron trials.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Mayo Clinic, NovoCure, Royal Philips, viewray

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS